BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 26080844)

  • 1. [Clinical analysis of newly diagnosed multiple myeloma patients with renal dysfunction].
    Zhu W; Lu J; Lu J; Hou J; Huang X; Chen W
    Zhonghua Yi Xue Za Zhi; 2015 Mar; 95(10):741-4. PubMed ID: 26080844
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Effect of Serum Free Light Chain on Renal Function and Prognosis in Patients with Newly Diagnosed Multiple Myeloma].
    Chen XD; Luo XF; Zu YP; Ye H; Li LL; Chen QL; Xie WZ; Yang T; Hu JD; Wei LX
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2019 Dec; 27(6):1862-1868. PubMed ID: 31839051
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [The roles of serum free light chain ratio in the diagnosis and prognosis of newly diagnosed multiple myeloma].
    Wang PF; Xu Y; Yan S; Yao Y; Zheng HF; Ma L; Jin S; Xu Y; Gong FR; Zhou JZ; Chang HR; Fu CC
    Zhonghua Xue Ye Xue Za Zhi; 2016 May; 37(5):377-82. PubMed ID: 27210871
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [A clinical analysis of 69 newly diagnosed multiple myeloma patients with renal insufficiency].
    An N; Li X; Shen M; Chen SL; Huang ZX
    Zhonghua Nei Ke Za Zhi; 2016 Oct; 55(10):764-768. PubMed ID: 27686436
    [No Abstract]   [Full Text] [Related]  

  • 5. Severe renal impairment as an adverse prognostic factor for survival in newly diagnosed multiple myeloma patients.
    Chen X; Luo X; Zu Y; Issa HA; Li L; Ye H; Yang T; Hu J; Wei L
    J Clin Lab Anal; 2020 Sep; 34(9):e23416. PubMed ID: 32710448
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Clinical characteristics and therapeutic efficacy of immunoglobin D multiple myeloma].
    Liu Y; Ke XY; Wang J; Jing HM; Wang JJ; Dong F; Wan WL; Zhang W
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2014 Dec; 22(6):1628-32. PubMed ID: 25543487
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Clinical Characteristics and Survival Analysis of Patients with IgD Multiple Myeloma].
    Gao XY; Ma YP; Chao Y; Fan L
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2021 Apr; 29(2):547-552. PubMed ID: 33812429
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Prognostic Impact of 1q21 Amplification in Newly Diagnosed Multiple Myeloma Patients Receiving Bortezomib-Based First-Line Treatment].
    Deng P; Zhou YL; Wei YL; Li P; Li F
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2017 Dec; 25(6):1696-1701. PubMed ID: 29262900
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Relationship of differences in immunoglobulin heavy/light chain pairs (Hevylite), selected laboratory parameters and stratification systems in different immunochemical types of multiple myeloma.
    Scudla V; Lochman P; Pika T; Minarik J; Zapletalova J; Bacovsky J
    Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2016 Mar; 160(1):84-93. PubMed ID: 26365929
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic Value of Serum Free Light Chains Measurements in Multiple Myeloma Patients.
    García de Veas Silva JL; Bermudo Guitarte C; Menéndez Valladares P; Rojas Noboa JC; Kestler K; Duro Millán R
    PLoS One; 2016; 11(11):e0166841. PubMed ID: 27893836
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lack of Renal Recovery Predicts Poor Survival in Patients of Multiple Myeloma With Renal Impairment.
    Sharma R; Jain A; Jandial A; Lad D; Khadwal A; Prakash G; Nada R; Aggarwal R; Ramachandran R; Varma N; Malhotra P
    Clin Lymphoma Myeloma Leuk; 2022 Aug; 22(8):626-634. PubMed ID: 35610119
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Clinical feature and efficacy of patients with multiple myeloma and renal impairment treated with bortezomib based chemotherapy].
    Xu Y; An G; Deng SH; Sui WW; Feng XY; Li F; Hao M; Wang YF; Qiu LG
    Zhonghua Xue Ye Xue Za Zhi; 2013 Apr; 34(4):304-8. PubMed ID: 23668201
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Renal Insufficiency in newly-diagnosed multiple myeloma: analysis according to International Myeloma Working Group consensus statement.
    Park S; Han B; Kim K; Kim SJ; Jang JH; Kim WS; Jung CW
    Anticancer Res; 2014 Aug; 34(8):4299-306. PubMed ID: 25075062
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Clinical Application of R-ISS Staging System in 412 Newly Diagnosed Patients with Multiple Myeloma].
    Chen HM; Wei W; Peng R; Shi HT; Chen XL; Wu LX; Zhou N; Zhou F
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2019 Feb; 27(1):110-114. PubMed ID: 30738456
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical features and treatment outcome of elderly multiple myeloma patients with impaired renal function.
    Chen J; Liu H; Li L; Liu Z; Song J; Wang G; Wang H; Ruan E; Ding K; Shao Z; Fu R
    J Clin Lab Anal; 2019 Jun; 33(5):e22888. PubMed ID: 31004381
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Effect of Serum Free Light Chain Ratio and Normalization Ratio after Treatment on Diagnosis and Prognosis of Patients with Newly Diagnosed Multiple Myeloma].
    Li ZQ; Tian WW; Guo YF; Ma LM
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2020 Aug; 28(4):1245-1250. PubMed ID: 32798406
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Renal impairment is not an independent adverse prognostic factor in patients with multiple myeloma treated upfront with novel agent-based regimens.
    Eleftherakis-Papapiakovou E; Kastritis E; Roussou M; Gkotzamanidou M; Grapsa I; Psimenou E; Nikitas N; Terpos E; Dimopoulos MA
    Leuk Lymphoma; 2011 Dec; 52(12):2299-303. PubMed ID: 22141916
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Renal insufficiency retains adverse prognostic implications despite renal function improvement following Total Therapy for newly diagnosed multiple myeloma.
    Khan R; Apewokin S; Grazziutti M; Yaccoby S; Epstein J; van Rhee F; Rosenthal A; Waheed S; Usmani S; Atrash S; Kumar S; Hoering A; Crowley J; Shaughnessy JD; Barlogie B
    Leukemia; 2015 May; 29(5):1195-201. PubMed ID: 25640885
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Treatment options and prognosis in newly diagnosed multiple myeloma patients].
    Wang L; Tang W; Wang Y; Xu L; Zhao WL; Wu W; Chen YB; Shen ZX; Hu J
    Zhonghua Xue Ye Xue Za Zhi; 2011 May; 32(5):308-12. PubMed ID: 21729598
    [TBL] [Abstract][Full Text] [Related]  

  • 20. LDH is an adverse prognostic factor independent of ISS in transplant-eligible myeloma patients receiving bortezomib-based induction regimens.
    Chim CS; Sim J; Tam S; Tse E; Lie AK; Kwong YL
    Eur J Haematol; 2015 Apr; 94(4):330-5. PubMed ID: 25135740
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.